Streetbeat News

Stock Prices

PNC

Piper Sandler has maintained its Neutral rating for PNC Financial Services Group (NYSE:PNC) and raised its price target from $130.00 to $131.00. PNC's shares are currently trading down 0.47% at $126.38 per share. A move to $131.00 would account for a 3.66% increase from the current share price.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 5:00 pm

AEIS

Advanced Energy Indus (NASDAQ:AEIS) has received positive analyst ratings in the last quarter, with 3 bullish and 4 somewhat bullish ratings. The average 12-month price target for AEIS has increased by 14.46% from the previous average, now standing at $127.38.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 5:00 pm

VRTX

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.6% on an annualized basis, producing an average annual return of 16.53%. If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $4,568.54 today.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 5:00 pm

RCL

Stifel has maintained its Buy rating for Royal Caribbean Gr (NYSE:RCL) but lowered its price target from $135.00 to $130.00. The current share price is $98.37, meaning the new target represents a 32.15% increase. Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 5:00 pm

BLRX

HC Wainwright & Co. has maintained its Buy rating for BioLine Rx (NASDAQ:BLRX) and raised its price target from $19.00 to $21.00. BioLine Rx's shares are trading up 11.36% over the last 24 hours. The new price target would account for a 971.43% increase from the current share price. BioLine Rx is a pre-commercial-stage biopharmaceutical company focused on oncology.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 5:00 pm

BLUE

An option alert has been issued for bluebird bio, with October 20 $4 calls seeing a sweep near the ask price. A total of 1271 contracts were traded at $0.25, compared to an open interest of 258. The company is expected to release its earnings on November 6 before the market opens. The reference price is $3.36.

Portfolio Pulse from Charles Gross

September 15, 2023 | 4:58 pm

LEN

Lennar Corporation's Q3 results led to a decline in its shares. Despite beating revenue and EPS estimates, the company reported a year-over-year decrease in the average sales price per home.

Portfolio Pulse from Benzinga Newsdesk

September 15, 2023 | 4:51 pm

IDXX

Stifel analyst Jonathan D. Block has reiterated a Hold rating on IDEXX Laboratories, Inc. (NASDAQ:IDXX), but lowered the price target to $500 from $525. The analyst notes that IDEXX is gaining market share and expects its diagnostics to play an increasingly important role in veterinary offices. However, he also warns of potential macroeconomic headwinds and ongoing practice capacity constraints that could hinder near-term volume improvements. The analyst predicts a modest growth in veterinary visits and a 2024 price increase of around 5% for IDEXX.

Portfolio Pulse from Nabaparna Bhattacharya

September 15, 2023 | 4:48 pm

QCOM

A significant amount of unusual options activity has been detected for Qualcomm (NASDAQ:QCOM), with a bearish stance being taken by a majority of investors. Of the 10 strange trades detected, 60% were bearish and 40% bullish. The total amount for the 7 puts was $409,638 and for the 3 calls was $115,945. Whales have been targeting a price range from $100.0 to $160.0 for Qualcomm over the last 3 months. The price of QCOM is currently down -0.71% at $113.23. Several experts have downgraded their ratings on Qualcomm, with price targets ranging from $100 to $145.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 4:48 pm

AMGN

A significant bearish stance has been taken on Amgen (NASDAQ:AMGN) by a large investor, as observed in the unusual options activity. The overall sentiment of these big-money traders is split between 36% bullish and 63% bearish. The whales have been targeting a price range from $250.0 to $280.0 for Amgen over the last 3 months. HSBC downgraded its action to Buy with a price target of $320, while Truist Securities downgraded its action to Hold with a price target of $260.

Portfolio Pulse from Benzinga Insights

September 15, 2023 | 4:48 pm